





- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th November,2021 . The above results have been subjected to limited review by the statutory auditors of the company
  - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
  - 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma,Inc.,USA and associate Rising Pharma Holding , Inc.,USA
  - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
  - 5) The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary , Suven Pharma , Inc., USA. Apart from the above the shortage or non- availability of vessels leading to delay in shipments , increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profiability.
  - 6) The other Income ( Standalone figures) includes an amount of Rs.3329.39 Lakhs pertaining to the Dividends received form our Subsidiary.And also the Current tax (Standalone figures) includes an amount of Rs.491.72 Lakhs tax paid on Such Dividend by our subsidiary.
  - 7) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

**For SUVEN PHARMACEUTICALS LTD**

Place : Hyderabad  
Date : 6th November,2021

**VENKAT JASTI**  
*Chairman & MD*  
**DIN: 00278028**



# SUVEN PHARMACEUTICALS LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

## Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30/09/2021	31/03/2021	30/09/2021	31/03/2021
	Un-Audited	Audited	Un-Audited	Audited
<b>A ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Property, Plant and Equipment	53,470.55	43,706.51	53,470.55	43,706.51
(b) Capital Work-in-Progress	1,671.98	9,614.91	1,671.98	9,614.91
(c) Other Intangible Assets	243.50	241.75	243.50	241.75
(d) Intangible assets under development	-	17.30	-	17.30
(e) Right of use of assets	198.47	167.53	198.47	167.53
(f) Financial Assets				
I. Investments	24,564.73	24,564.73	36,588.14	36,119.40
II. Loans	6.20	6.20	6.20	6.20
III. Other Financial Assets	514.06	495.18	514.06	495.18
(g) Deferred tax assets (net)	-	-	-	-
(h) Other non current assets	575.82	599.21	575.82	599.21
<b>Total Non-Current assets</b>	<b>81,245.31</b>	<b>79,413.32</b>	<b>93,268.72</b>	<b>90,967.99</b>
<b>2 Current assets</b>				
(a) Inventories	26,462.27	20,108.04	26,462.27	20,108.04
(b) Financial Assets			-	
I. Investments	20,947.09	18,059.38	20,947.09	18,059.38
II. Trade Receivables	16,390.24	10,238.22	16,390.24	10,238.22
III. Cash and Cash equivalents	1,600.79	709.14	1,733.78	718.22
IV. Bank balances other than (III) above	258.45	247.10	258.45	247.10
V. Loans	19.49	21.78	19.49	21.78
VI. Other Financial assets	-	-	-	-
(c) Current Tax asset (net)	-	224.67	-	224.67
(d) Other current assets	7,172.13	6,861.11	7,172.14	6,861.11
<b>Total Current assets</b>	<b>72,850.46</b>	<b>56,469.44</b>	<b>72,983.46</b>	<b>56,478.52</b>
<b>TOTAL - ASSETS</b>	<b>154,095.77</b>	<b>135,882.76</b>	<b>166,252.18</b>	<b>147,446.51</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 EQUITY</b>				
(a) Equity Share Capital	2,545.65	2,545.65	2,545.65	2,545.65
(b) Other Equity	121,049.05	103,972.68	133,205.45	115,535.18
<b>Equity attributable to owners of the company</b>	<b>123,594.70</b>	<b>106,518.33</b>	<b>135,751.10</b>	<b>118,080.83</b>
<b>2 LIABILITIES</b>				
(a) Financial Liabilities				
I. Lease Liability	105.46	73.90	105.46	73.90
II. Borrowings	3,507.94	3,559.09	3,507.94	3,559.09
(b) Provisions	664.60	664.60	664.60	664.60
(c) Deferred tax Liabilities (net)	3,324.84	3,093.29	3,324.84	3,093.29
(d) Other non current liabilities	-	-	-	-
<b>Total non-current liabilities</b>	<b>7,602.84</b>	<b>7,390.88</b>	<b>7,602.84</b>	<b>7,390.88</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
I. Lease Liability	109.09	106.82	109.09	106.82
II. Borrowings	9,345.21	10,563.76	9,345.21	10,563.76
III. Trade payables			-	
a) To Micro & Small Enterprises	920.16	996.25	920.16	996.25
b) Other than Micro & Small Enterprises	8,901.32	7,296.89	8,901.32	7,296.89
IV. Other Financial Liabilities	2,481.38	2,522.75	2,481.39	2,524.00
(b) Current Tax liabilities (Net)	127.21	-	127.21	-
(c) Provision Employee benefits	314.90	260.72	314.90	260.72
(d) Other Current liabilities	698.96	226.36	698.96	226.36
	<b>22,898.23</b>	<b>21,973.55</b>	<b>22,898.24</b>	<b>21,974.80</b>
<b>Total Liabilities</b>	<b>30,501.07</b>	<b>29,364.43</b>	<b>30,501.08</b>	<b>29,365.68</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>154,095.77</b>	<b>135,882.76</b>	<b>166,252.18</b>	<b>147,446.51</b>

For Suvan pharmaceuticals Ltd

Place : Hyderabad

Date: 6th November, 2021

Venkat Jasti  
Chairman & MD

<b>SUVEN PHARMACEUTICALS LIMITED</b>			
<b>Standalone Statement of Cash flows for the period ended 30th September, 2021</b>			
(All amounts in Indian Rupees in Lakhs, unless otherwise stated)			
Particulars		For the period ended 30th September 2021	For the period ended 30th September 2020
<b>A. Cash flow from operating activities</b>			
Profit before tax		25903.86	19,566.39
<b>Adjustments :</b>			
Depreciation and amortisation expense		1775.48	1,439.72
Interest Income		(16.60)	(18.05)
Finance Cost		330.06	536.30
Gain on sale of Current Investment		(438.34)	(155.39)
Dividend received from WOS		(3329.39)	-
Effects of foreign exchange rates ( Unrealized)		(51.83)	(61.44)
Loss/(Profit) on disposal of Property, plant & equipment		(0.06)	-
<b>Operating profit before working capital changes</b>		<b>24173.18</b>	<b>21307.53</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>			
Trade Receivables		(6060.03)	1,087.40
Inventories		(6354.23)	(2,261.60)
Other non current assets		(30.94)	819.47
Other current assets		(308.49)	(3,222.96)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>			
Trade Payables		1519.94	917.70
Short term provision		(1.75)	223.34
Other financial liabilities		642.47	(615.60)
Other current liabilities		462.45	(133.46)
<b>Cash generated from operating activities</b>		<b>14042.59</b>	<b>18121.82</b>
Income taxes paid (net of refunds)		(5642.47)	(4,059.96)
<b>Net Cash flows from operating activities</b>	<b>(A)</b>	<b>8400.12</b>	<b>14061.86</b>
<b>B. Cash flow from Investing activities</b>			
Payments for Purchase of property, plant and equipment		(4245.15)	(6,284.76)
Proceeds from sale of Property, plant & equipment		0.06	-
Dividend received from WOS		3329.39	-
Fixed deposits/margin money-placed/matured		(18.89)	-
Sale/(purchase) of mutual funds		(2449.37)	(3,888.02)
Bank balances not considered as cash and cash equivalents		(7.70)	(199.84)
<b>Net cash flow from / ( used in) investing activities</b>	<b>(B)</b>	<b>(3391.65)</b>	<b>(10,372.62)</b>
<b>C. Cash flows from financing activities</b>			
(Repayment)/Proceeds from long term borrowings		(125.91)	(3,623.43)
(Repayment)/Proceeds from short term borrowings		(1167.91)	416.49
Other non current financial assets		-	1.37
Other current financial assets		2.30	(9.29)
Changes In Lease Liability		33.83	94.64
Finance Cost		(330.06)	(536.30)
Interest received		16.60	18.05
Dividends paid to equity holders (including dividend distribution tax)		(2545.65)	-
<b>Net cash flow from / (used In) financing activities</b>	<b>(C)</b>	<b>(4116.80)</b>	<b>(3,638.47)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(A+B+C)</b>	<b>891.68</b>	<b>50.77</b>
Cash and cash equivalents as at the beginning of the year		709.14	1,157.68
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		(0.03)	1.71
<b>Cash and cash equivalents at the end of the year</b>		<b>1600.79</b>	<b>1210.16</b>
Cash and cash equivalents		1600.79	1,210.16
Balances per statement of cash flows		<b>1600.79</b>	<b>1,210.16</b>
<b>For Suven Pharmaceuticals Ltd</b>			
<b>Venkateswarlu Jasti</b>			
<b>Chairman &amp; M D</b>			
<b>DIN: 00278028</b>			
<b>Place : Hyderabad</b>			
<b>Date : 06th November,2021</b>			

<b>SUVEN PHARMACEUTICALS LIMITED</b>			
<b>Consolidated Statement of Cash flows for the period ended 30th September, 2021</b>			
(All amounts in Indian Rupees in Lakhs, unless otherwise stated)			
Particulars		For the period ended 30th September 2021	For the period ended 30th September 2020
<b>A. Cash flow from operating activities</b>			
Profit before tax		26684.97	21,470.45
<b>Adjustments :</b>			
Depreciation and amortisation expense		1775.48	1,439.72
Interest Income		(16.60)	(18.05)
Finance Cost		330.06	536.30
Gain on sale of Current Investment		(438.34)	(155.39)
Effects of foreign exchange rates ( Unrealized)		(51.83)	(61.44)
Loss/(Profit) on disposal of Property,plant & equipment		(0.06)	-
<b>Operating profit before working capital changes</b>		<b>28283.68</b>	<b>23211.59</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>			
Trade Receivables		(6060.03)	1,087.40
Inventories		(6354.23)	(2,261.60)
Other non current assets		(30.94)	819.47
Other current assets		(308.49)	(3,222.96)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>			
Trade Payables		1519.94	917.70
Short term provision		(1.75)	223.34
Other financial liabilities		641.21	(619.98)
Other current liabilities		462.45	(133.46)
<b>Cash generated from operating activities</b>		<b>18151.84</b>	<b>20021.50</b>
Income taxes paid (net of refunds)		(5880.68)	(4,059.96)
<b>Net Cash flows from operating activities</b>	<b>(A)</b>	<b>12271.16</b>	<b>15961.54</b>
<b>B. Cash flow from Investing activities</b>			
Payments for Purchase of property, plant and equipment		(4245.15)	(6,284.76)
Proceeds from sale of Property, plant & equipment		0.06	-
Changes in Investments		(468.73)	(1,907.02)
Fixed deposits/margin money-placed/matured		(18.89)	-
Sale/(purchase) of mutual funds		(2449.37)	(3,888.02)
Foreign currency translation reserve		50.99	(0.14)
Bank balances not considered as cash and cash equivalents		(7.70)	(199.84)
<b>Net cash flow from /( used in) investing activities</b>	<b>(B)</b>	<b>(7138.78)</b>	<b>(12279.78)</b>
<b>C. Cash flows from financing activities</b>			
(Repayment)/Proceeds from long term borrowings		(125.91)	(3,623.43)
(Repayment)/Proceeds from short term borrowings		(1167.91)	416.49
Other non current financial assets		0.00	1.37
Other current financial assets		2.30	(9.29)
Changes In Lease Liability		33.83	94.64
Finance Cost		(330.06)	(536.30)
Interest received		16.60	18.05
Dividends paid to equity holders (including dividend distribution tax)		(2545.65)	-
<b>Net cash flow from /(used In) financing activities</b>	<b>(C)</b>	<b>(4116.80)</b>	<b>(3638.47)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(A+B+C)</b>	<b>1015.58</b>	<b>43.29</b>
Cash and cash equivalents as at the beginning of the year		718.23	1,169.53
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		(0.03)	1.71
<b>Cash and cash equivalents at the end of the year</b>		<b>1733.78</b>	<b>1214.53</b>
Cash and cash equivalents		1733.78	1,214.53
Balances per statement of cash flows		<b>1733.78</b>	<b>1214.53</b>
<b>For Suven Pharmaceuticals Ltd</b>			
<b>Venkateswarlu Jasti</b>			
<b>Chairman &amp; M D</b>			
<b>DIN: 00278028</b>			
<b>Place : Hyderabad</b>			
<b>Date : 06th November,2021</b>			